Securities Fraud Investigation Into Dr. Reddy’s Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Dr. Reddy’s Laboratories (“Dr. Reddy’s” or the “Company”) (NYSE: RDY) on behalf of investors concerning the Company’s possible violations of federal securities laws.

IF YOU ARE AN INVESTOR WHO LOST MONEY ON DR. REDDY’S LABORATORIES (RDY), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS.

What Is The Investigation About?

On July 22, 2026, Dr. Reddy’s announced its first quarter fiscal 2027 earnings, reporting, among other things, earnings per share of only $0.06, due in part to the adverse impact of a ₹2.4 billion provision related to out-of-specification semaglutide batches. CEO Erez Israeli said “The quarter's EBITDA margin was adversely impacted by semaglutide-related challenges, including lower sales, provision for rejected batches, loss of production-linked incentives and other associated costs.”

On this news, the price of Dr. Reddy’s Laboratories stock price fell $1.18, or 9.4%, to close at $11.38 on July 22, 2026, thereby injuring investors.

Contact Us To Participate or Learn More:

If you purchased Dr. Reddy’s Laboratories securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

The Law Offices of Frank R. Cruz,
2121 Avenue of the Stars, Suite 800,
Century City, California 90067
Call us at: 310-914-5007
Email us at: [e-mail]
Visit our website at: www.frankcruzlaw.com.
Follow us for updates on Twitter at twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.